PD-1 × VEGF bispecifics after ivonescimab
A bispecific has three pharmacological edges over a two-drug combo: higher local concentration in the tumor; VEGF is itself an immune suppressor, so blocking it also frees dendritic cells and T-cell entry; vessel normalization lets T cells in.
Most molecules hit PD-1 × VEGF; BioNTech’s BNT327 / pumitamig hits PD-L1 × VEGF-A.
#AACR26 Junshi reports PD‑1×VEGF antibody in MSS colorectal cancer
a Phase II data for JS207 (PD‑1 × VEGF bispecific) combined with XELOX as 1L therapy in metastatic CRC — a setting where IO has historically failed.
https://
aacrjournals.org/cancerres/arti
cle/86/8_Supplement/CT152/783100/Abstract-CT152-Preliminary-results-from-a-phase-II?searchresult=1
…
• All patients were MSS/pMMR CRC —
Heat 22 · 16 likes · 2 replies · 4 reposts
Yong Gao, Zhiwei Li, Jianwei Yang, Shuqing Jin, Yiyi Yu, Chang Wang, Xiwen Huang, Jingdong Zhang, Yanhong Gu, Shuqin Ni, Yanlai Sun, Shirong Cai, Liang Han, Xinjun Liang, Haichuan Su, Chenxi Wang, Zhenyu Xu, Jing Xu, Chengbo Jia, Jianjun Zou, Lin Shen
Read the abstract →Jian Zhou, Guoming Shi, Yongsheng Ge, Shuijun Zhang, Xiwen Huang, Shunda Du, Yong Gao, Guohong Han, Xiaoyong Huang, Zhenda Wang, Junliang Li, Jing Xu, Jiazheng Yan, Jianjun Zou, Jia Fan
Read the abstract →Source: Minhua Chu · x.com